Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQV3IM)

• Drug Name: SAR445088 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic inflammatory demyelinating polyneuropathy	8C01.3	Phase 2	[1]
Immune thrombocytopenia	3B64	Phase 2	[2]
Autoimmune haemolytic anaemia	3A20	Phase 1	[3]
Cold agglutinin disease	3A20.1	Phase 1	[4]

• Cross-matching ID: TTD Drug ID: DMQV3IM

Molecule-Related Drug Atlas

Drug(s) Targeting Complement C1s component (C1S)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cinryze	DMVIKJZ	Hereditary angioedema	4A00.14	Approved	[6]
Sutimlimab	DMY7WH1	Cold type autoimmune haemolytic anemia	3A20.1	Approved	[7]
TS01	DMNTVUK	Stroke	8B20	Phase 1	[8]
SHP616	DMO0CA8	Neuromyelitis optica	8A43	Phase 1	[9]
ANX005	DMAESIY	Neurodegenerative disorder	8A20-8A23	Phase 1	[10]
TNT009	DMSKF29	Bullous pemphigoid	EB41.0	Phase 1	[9]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[11]
PMID16460935C28	DM8BKI4	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement C1s component (C1S)	TT7LRQH	C1S_HUMAN	Inhibitor	[5]

References

• [1] ClinicalTrials.gov (NCT04658472) A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04669600) A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04802057) An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088. U.S.National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04269551) A Multicenter, Phase 1b, Open Label, Nonrandomized, Single Dose Study Evaluating the Safety, Tolerability and Activity of BIVV020 in Adults With Cold Agglutinin Disease. U.S.National Institutes of Health.
• [5] First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023 Apr;16(4):673-685.
• [6] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [7] Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531.
• [8] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [12] A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2200-4.